Pelthos Therapeutics Inc. (PTHS) stock
PTHSNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$6.84−0.31 (-4.34%)
Close on Nov 17, 2026Market cap $26.19MP/E –Yield –
Pelthos Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Pelthos Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $1.31M, down 7.4% year over year. For fiscal 2025 it was $1.23M, up 4.2% from the year before.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.23M | +4.2% |
| FY2024 | Dec 31, 2024 | $1.18M | -54.3% |
| FY2023 | Dec 31, 2023 | $2.58M | +558.5% |
| FY2022 | Dec 31, 2022 | $391.73K | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $600.00K | +16.5% |
| Q1 FY2026 | Mar 31, 2026 | $186.00K | -4.1% |
| Q4 FY2025 | Dec 31, 2025 | $374.00K | +31.2% |
| Q3 FY2025 | Sep 30, 2025 | $145.00K | -65.1% |
| Q2 FY2025 | Jun 30, 2025 | $515.00K | +3875.3% |
| Q1 FY2025 | Mar 31, 2025 | $194.00K | -58.4% |
| Q4 FY2024 | Dec 31, 2024 | $285.00K | -87.6% |
| Q3 FY2024 | Sep 30, 2024 | $415.00K | +744.7% |
| Q2 FY2024 | Jun 30, 2024 | $12.96K | -74.1% |
| Q1 FY2024 | Mar 31, 2024 | $466.61K | +150.7% |
| Q4 FY2023 | Dec 31, 2023 | $2.29M | – |
| Q3 FY2023 | Sep 30, 2023 | $49.13K | – |
| Q2 FY2023 | Jun 30, 2023 | $49.96K | – |
| Q1 FY2023 | Mar 31, 2023 | $186.12K | – |
See a number that looks wrong?